Abstract
Purpose: To estimate the rate of new-onset seizure in ADHD patients in relation to ADHD pharmacotherapy. Methods: A retrospective cohort study of 34,727 patients, ages 6 to 17, with at least two insurance claims bearing ADHD diagnoses during 2003 in the United Healthcare database. Incidence of seizure was calculated for observation time during treatment with atomoxetine and stimulants/bupropion. Results: Seizure incidence among ADHD patients was 4.5/1,000 person-years (p-y; 95% confidence interval 3.7 – 5.5). ADHD patients who received any ADHD medication had an incidence of 3.8/1,000 p-y (3.0 – 4.8) compared to 8.7 (5.8 – 12.4) for patients who did not receive any ADHD medication. The relative risk (RR) for current vs non-use of atomoxetine was 1.1 (0.6 – 2.1). For stimulants and bupropion, the RR for current vs non-use was 0.8 (0.6 – 1.3). Elevated seizure risks were found in association with central nervous system (CNS) disease (OR 3.9, 1.2 – 10.9), CNS medications (OR 2.2, 1.3 – 3.6), metabolic disease (OR 2.9, 1.1 – 6.8), and psychiatric disease risk factors (OR 1.7, 1.1 – 2.6). Conclusions: In this study, there was no statistically significant association between use of atomoxetine or stimulants and seizure risk in children ages 6 to 17 years with ADHD and without prior seizure disorder.
Keywords: ADHD, epilepsy, seizure, stimulants, atomoxetine, retrospective cohort study
Current Drug Safety
Title: The Effect of Pharmacotherapy for Attention Deficit Hyperactivity Disorder on Risk of Seizures in Pediatric Patients as Assessed in an Insurance Claims Database
Volume: 3 Issue: 2
Author(s): Andrew T. McAfee, Karen C. Holdridge, Catherine B. Johannes, Kenneth Hornbuckle and Alexander M. Walker
Affiliation:
Keywords: ADHD, epilepsy, seizure, stimulants, atomoxetine, retrospective cohort study
Abstract: Purpose: To estimate the rate of new-onset seizure in ADHD patients in relation to ADHD pharmacotherapy. Methods: A retrospective cohort study of 34,727 patients, ages 6 to 17, with at least two insurance claims bearing ADHD diagnoses during 2003 in the United Healthcare database. Incidence of seizure was calculated for observation time during treatment with atomoxetine and stimulants/bupropion. Results: Seizure incidence among ADHD patients was 4.5/1,000 person-years (p-y; 95% confidence interval 3.7 – 5.5). ADHD patients who received any ADHD medication had an incidence of 3.8/1,000 p-y (3.0 – 4.8) compared to 8.7 (5.8 – 12.4) for patients who did not receive any ADHD medication. The relative risk (RR) for current vs non-use of atomoxetine was 1.1 (0.6 – 2.1). For stimulants and bupropion, the RR for current vs non-use was 0.8 (0.6 – 1.3). Elevated seizure risks were found in association with central nervous system (CNS) disease (OR 3.9, 1.2 – 10.9), CNS medications (OR 2.2, 1.3 – 3.6), metabolic disease (OR 2.9, 1.1 – 6.8), and psychiatric disease risk factors (OR 1.7, 1.1 – 2.6). Conclusions: In this study, there was no statistically significant association between use of atomoxetine or stimulants and seizure risk in children ages 6 to 17 years with ADHD and without prior seizure disorder.
Export Options
About this article
Cite this article as:
McAfee T. Andrew, Holdridge C. Karen, Johannes B. Catherine, Hornbuckle Kenneth and Walker M. Alexander, The Effect of Pharmacotherapy for Attention Deficit Hyperactivity Disorder on Risk of Seizures in Pediatric Patients as Assessed in an Insurance Claims Database, Current Drug Safety 2008; 3 (2) . https://dx.doi.org/10.2174/157488608784529233
DOI https://dx.doi.org/10.2174/157488608784529233 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Antimicrobial and Structural Properties of Metal Ions Complexes with Thiosemicarbazide Motif and Related Heterocyclic Compounds
Current Medicinal Chemistry β-Catenin/TCF-4 Signaling Regulates Susceptibility of Macrophages and Resistance of Monocytes to HIV-1 Productive Infection
Current HIV Research Neuroprotective Actions of Flavones and Flavonols: Mechanisms and Relationship to Flavonoid Structural Features
Central Nervous System Agents in Medicinal Chemistry The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimers Disease
Current Topics in Medicinal Chemistry AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Venom Peptide Modulators of the Immune System
Inflammation & Allergy - Drug Targets (Discontinued) Vaccine-Associated Neurological Adverse Events: A Case Report and Literature Review
Current Pharmaceutical Design Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets The Role of the Urokinase Receptor in Epilepsy, in Disorders of Language, Cognition, Communication and Behavior, and in the Central Nervous System
Current Pharmaceutical Design Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease
Current Pharmaceutical Design Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design Toll-Like Receptor System in the Human Endometrium
Current Immunology Reviews (Discontinued) ABC Transporters in Neurological Disorders: An Important Gateway for Botanical Compounds Mediated Neuro-Therapeutics
Current Topics in Medicinal Chemistry Inactivated- or Killed-Virus HIV/AIDS Vaccines
Current Drug Targets - Infectious Disorders Localised Delivery of Therapeutic Agents to CNS Malignancies: Old and New Approaches
Current Pharmaceutical Biotechnology Genomic Databases and the Search of Protein Targets for Protozoan Parasites
Current Drug Targets Regulatory T Cells and Tolerogenic Dendritic Cells as Critical Immune Modulators in Atherogenesis
Current Pharmaceutical Design Extrapulmonary Tuberculosis- Its Management and Control
Current Drug Therapy Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy